Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.46 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10271507 | 0.96 | PDE4B (0.48) | PDE4BCNR2KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL870809 | 0.87 | PDE4B (0.50) | PDE4BKDM4ESMN1; SMN2HSD17B10TP53 | |
| SCHEMBL870810 | 0.87 | PDE4B (0.50) | PDE4BKDM4ESMN1; SMN2HSD17B10TP53 | |
| SCHEMBL870026 | 0.86 | PDE4B (0.45) | PDE4BCNR2CNR1 | |
| SCHEMBL870027 | 0.86 | PDE4B (0.45) | PDE4BCNR2CNR1 | |
| SCHEMBL3022989 | 0.85 | PDE4B (0.52) | PDE4BCNR2KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL3022993 | 0.85 | PDE4B (0.52) | PDE4BCNR2KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL870912 | 0.85 | PDE4B (0.44) | PDE4BCNR2CNR1 | |
| SCHEMBL3032429 | 0.85 | PDE4B (0.52) | PDE4BCNR2KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL3032431 | 0.85 | PDE4B (0.52) | PDE4BCNR2KDM4ESMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077801-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | PDE4B 2/4885CNR2 2229/4885KDM4E 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.